Since its clinical introduction in 1998, the topoisomerase I inhibitor irinotecan has been
widely used in the treatment of solid tumors, including colorectal, pancreatic, and lung …

Abstract The 4-anilinoquinazolines (gefitinib, erlotinib and lapatinib) are members of a class
of potent and selective inhibitors of the human epidermal growth factor receptor (HER) family …

Drug interactions are an on-going concern in the treatment of cancer, especially when
targeted therapies, such as tyrosine kinase inhibitors (TKI) or mammalian target of …

Highlights•Complete overview on exposure–response relationships for TKIs used in solid
tumors.•Dose individualization is expected to minimize toxicity and improve efficacy.•For …

Kinase domain mutations of the EGF receptor (EGFR) are common oncogenic events in lung
adenocarcinoma. Here, we explore the dependency upon asymmetric dimerization of the …

Signalling pathways that emerge from EGFR activation are critical in colon cancer (CC)
biology. Its targeting with specific drugs has opened a new window in the treatment of this …

AIM: To review the clinical trials for the development in drugs for chemotherapeutic treatment
of colorectal cancer (CRC). METHODS: A systematic review identified randomized …

Background: Targeting the epidermal growth factor receptor and angiogenesis have proven
useful strategies against metastatic colorectal cancer. The benefit of combining inhibitors of …

Although significant advances have been made in the treatment of metastatic colorectal
cancer (CRC), prognosis remains poor, with a 5-year survival of less than 10%. Monoclonal …

Background To determine the maximum tolerated dose (MTD) and safety, and explore
efficacy and biomarkers of vandetanib with cetuximab and irinotecan in second-line …